Specialty Pharmacy

Top news of the day from across the health care landscape.

Researchers in the JADE MONO-1 study investigated whether patients aged 12 years and older with moderate to severe atopic dermatitis would achieve with abrocitinib could achieve clear or almost clear skin with abrocitinib.

Top news of the day from across the health care landscape.

Jesse C. Dresser, Esq explains the current climate of PBM reform at the NASP Annual Meeting in Washington, DC.

A newly-developed machine learning system may help act as an alert system for potential adverse effects from drug-drug interactions.

Top news of the day from across the health care landscape.

Officials with the FDA have approved adalimumab-afzb (Abrilada, Pfizer), a biosimilar to Humira, for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn disease, ulcerative colitis, and plaque psoriasis.

cvMOBIUS will examine lipid management and the effectiveness of evolocumab (Repatha, Amgen) on cardiovascular outcomes.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss the goals and importance of his company, Stack, during the NASP Annual Meeting in Washington, DC.

Crizanlizumab-tmca (Adakveo, Novartis) is approved to reduce the frequency of vaso-occlusive crises in patients aged 16 years and older with sickle cell disease.

Top news of the day from across the health care landscape.

The FDA granted accelerated approval to zanubrutinib (Brukinsa, BeiGene) for the treatment of mantle cell lymphoma in adults who have received at least 1 prior therapy.

Jonathan Ogurchak, PharmD, CSP, sits down with Specialty Pharmacy Times to discuss how vertical integration might affect biosimilar availability in specialty pharmacy during the NASP Annual Meeting in Washington, DC.

The COAST-X study evaluated ixekizumab (Taltz, Eli Lilly) in patients with non-radiographic axial spondyloarthritis.

With vincristine in short supply, Teva will resume production of the chemotherapy agent following its previous decision to remove the product from the market.

The largest study of its kind has found that 40% of the European population carries a genetic variant that leads to antibody resistance against anti-tumor necrosis factor (TNF) drugs, infliximab and adalimumab, and lose response.

A study reveals that axial psoriatic arthritis and ankylosing spondylitis with psoriasis are different diseases with different genetics, demographics, and disease expression.

Findings from a phase 3 study reinforced the safety and efficacy of rituximab (Rituxan, Genentech) as a treatment for patients with pemphigus vulgaris.

Top news of the day from across the health care landscape.

Jesse C. Dresser, Esq explains how DIR fees affect specialty pharmacists at the NASP Annual Meeting in Washington, DC.

Weight loss surgery found to cut the overall risk of developing cancers linked to obesity by 20%.

Neuromyelitis optica is the fourth chronic disease that hematopoietic stem cell transplantation has appeared to reverse.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Survivors of long-term diffuse large B-cell lymphoma found to have a higher risk of developing a second primary cancer.

Top news of the day from across the health care landscape.

Annual Award Celebrates Electronic Health Records, Health Systems and Pharmacy Industry Leaders for Improving Patient Safety and Workflow Efficiency

A study looked at the incidence of thrombosis in patients being treated with ibrutinib for hematologic malignancies.

FDA breakthrough designation is based on data for nivolumab plus ipilimumab in a study evaluating the immuno-oncology combination in patients with advanced hepatocellular carcinoma previously treated with sorafenib.